• BioMarin Pharmaceutical average return on equity for 2023 was 2.57, a 41.99% increase from 2022.
• BioMarin Pharmaceutical average return on equity for 2022 was 1.81, a 81.51% increase from 2021.
• BioMarin Pharmaceutical average return on equity for 2021 was 9.79, a 29.87% decline from 2020.

Roe - return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.